Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
featured
  • 0 views
  • 29 Jul, 2021
  • 1 location
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg

cyclophosphamide
anca
nasal abnormality
immunosuppression
steroid therapy
  • 21 views
  • 19 Sep, 2021
  • 81 locations
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.

Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies

  • 9 views
  • 26 Jan, 2021
  • 13 locations
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil

The anti-interleukin-5 monoclonal antibody mepolizumab is approved as an add-on therapy in Europe, Canada, USA, and other countries, to standard of care for the treatment of patients with severe

  • 0 views
  • 23 Jan, 2021
  • 2 locations
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with

  • 22 views
  • 18 Sep, 2021
  • 1 location
Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients.

have a better response to the current available biological therapies , such as the administration of mepolizumab (anti IL-5 antibody). Eosinophilic asthma is associated to a more severe clinical

  • 0 views
  • 21 Aug, 2021
  • 1 location
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in COPD

antibiotics
fluticasone
muscarinic antagonists
albuterol
cigarette smoke
  • 379 views
  • 24 Jul, 2021
  • 233 locations
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the

  • 1 views
  • 10 Jul, 2021
  • 48 locations
Mepolizumab in Episodic Angioedema With Eosinophilia

, fever, and weight gain. During episodes, the body has very high numbers of white blood cells, especially a kind called eosinophils. Researchers think a drug called mepolizumab could help.

monoclonal antibody
follicle stimulating hormone
corticosteroids
myalgias
swelling
  • 0 views
  • 31 May, 2021
  • 1 location
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index

  • 0 views
  • 26 Jan, 2021
  • 1 location